Skip Navigation



JAC Advance Access published online on July 10, 2007
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkm259
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
60/3/457    most recent
dkm259v2
dkm259v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Knaapen, H. K. A.
Right arrow Articles by Barrera, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knaapen, H. K. A.
Right arrow Articles by Barrera, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Article

Therapy for Whipple's disease

Hanneke K. A. Knaapen and Pilar Barrera*

Department of Rheumatology, University Medical Centre Nijmegen St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands

* Corresponding author. Tel: +31-24-361-45-80; Fax: +31-24-354-14-33; E-mail: p.barrera{at}reuma.umcn.nl

Whipple's disease was first described in 1907, the genomic composition of the causative organism, Tropheryma whipplei, was unravelled in 2003 and its in vitro susceptibility to antibiotics started to be explored in 2004–05. Still today, this knowledge is not fully applied in the recommendations for the therapy of this disease. In this paper, we summarize the current recommendations on antimicrobial therapy for Whipple's disease and propose a shift in the maintenance therapy.

Key Words: Tropheryma whipplei , sulphonamides , trimethoprim , antimicrobial therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 PNHome page
P K Panegyres
Diagnosis and management of Whipple's disease of the brain
Practical Neurology, October 1, 2008; 8(5): 311 - 317.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Bakkali, F. Fenollar, J.-M. Rolain, and D. Raoult
Comment on: Therapy for Whipple's disease
J. Antimicrob. Chemother., April 1, 2008; 61(4): 968 - 969.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. K. A. Knaapen and P. Barrera
Therapy for Whipple's disease--authors' response
J. Antimicrob. Chemother., April 1, 2008; 61(4): 969 - 970.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.